Inhibitor of D-amino acid oxidase (DAAO)

Novel Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers

Non-steroidal selective estrogen receptor modulator (SERM)

Inhibitor of the inflammatory responses via NF

The first human arylsulfatase A reversible inhibitor, impairing mouse oocyte fertilization

Selective alpha-7 agonist

Novel potent and selective BRAF inhibitor

Novel selective estrogen receptor degrader (SERD), inducing regression in a tamoxifen-resistant breast cancer xenograft

Novel dual inhibitor of the fatty acid amide hydrolase (FAAH) and the cyclooxygenase (COX) enzymes

Regulator and promotor of immune functions, enhancing the role of macrophages, inhibiting bacteria growth, improving the protein metabolism, and regulating liver function

Natural inhibitor of recombinant purified ClpXP and ClpYQ AAA+ proteases, exhibitung potent antibacterial activity against H. pylori, including multidrug-resistant strains

Selective ecto-ATPase inhibitor, preventing metabolism of P2 purinoceptor agonists

P2T (P2YADP) purinoceptor antagonist

Novel inhibitor of Ark1, the fission yeast member of the conserved Aurora kinase family

Novel selective inhibitor of PREP, displaying great selectivity over FAP, while also not inhibiting the DPPs.

Potent tumor-homing tripeptide, targeting heat shock protein 70 (HSP70)

Long-acting beta-2 adrenergic agonist

Long-acting beta-2 adrenergic agonist

Negative control for ARCC-4, binding androgen receptors (AR) without inducing degradation.

Anticancer agent, inducing apoptosis mediated at least in part by the ERS pathway and inhibiting hepatoma tumor growth

Highly potent and selective fluorescent probe of Rho kinase (ROCK)

Highly potent CK2α inhibitor (K(i) = 0.5 nM), revealing high selectivity for CK2α in a panel of 140 protein kinases

Novel inhibitor of lactate transporters (monocarboxylate transporters; MCTs)

Novel immunosuppressant and monocarboxylate transporter inhibitor, reducing immune responses both in vitro and in vivo, maintaining long-term graft survival, and inducing operational tolerance

Novel 5-hydroxytryptamine 1B (5-HT 1B ) autoreceptor antagonist

Novel inverse agonist of Mas G-protein signaling, dose-dependently inhibiting inositol 1,4,5-trisphosphate accumulation in AdMas-infected cells, and attenuating the sarcomeric organization and cell enlargement observed in Mas overexpressing myocytes

Novel Rho kinase inhibitor

Novel potent androgen receptor (AR) degrader, exhibiting excellent AR binding affinity (85%) and AR degradation efficacy at 30 μM

Novel AR antagonist, targeting the AR AF2, showing excellent AR antagonistic activity (IC 50 = 0.47 μM) and peptide displacement activity (IC 50 = 18.05 μM)

Novel Antiandrogen, Suppressing Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth